Compare IAF & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAF | TMCI |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 120.4M |
| IPO Year | N/A | 2021 |
| Metric | IAF | TMCI |
|---|---|---|
| Price | $12.45 | $4.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.77 |
| AVG Volume (30 Days) | 21.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $4.36 | $1.17 |
| 52 Week High | $14.54 | $7.78 |
| Indicator | IAF | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 55.78 |
| Support Level | $12.00 | $3.84 |
| Resistance Level | $13.21 | $4.62 |
| Average True Range (ATR) | 0.22 | 0.40 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 8.08 | 39.89 |
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.